Scholar Rock Holding Corporation
SRRK
Clasificación en acciones
#3424
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Precio por acción
$41.58
Última sincronización: 2026-10-20
Capitalización bursátil
$5.06B
Cambio (1 día)
3.34%
Cambio (1 año)
47.62%
País
US
Comercio Scholar Rock Holding Corporation (SRRK)
Categoría
Healthcare
Ganancias de Scholar Rock Holding Corporation (SRRK)
Ganancias en Jun 2026 TTM: $-408.59M
Secondo gli ultimi rapporti finanziari di Scholar Rock Holding Corporation, gli utili attuali della società sono $-408.59M. Nel 2023, la società ha registrato un utile di $-165.79M, una disminución en comparación con agli utili del 2022, che erano di $-134.50M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Scholar Rock Holding Corporation desde 2016 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-408.59M | 65.90% |
| 2024 | $-246.29M | 48.56% |
| 2023 | $-165.79M | 23.26% |
| 2022 | $-134.50M | 2.05% |
| 2021 | $-131.80M | 52.40% |
| 2020 | $-86.48M | 69.57% |
| 2019 | $-51.00M | 3.39% |
| 2018 | $-49.33M | 97.34% |
| 2017 | $-25.00M | 54.22% |
| 2016 | $-16.21M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,391.00% |
US
|
|
| $-3.09B | 655.52% |
US
|
|
| $-4.02B | 882.94% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -577.41% |
NL
|
